8.3 Non-Sterile Compounding and NAPRA Standards
Key Takeaways
- The NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations establish three distinct levels of compounding risk: Level A (simple/routine, designated clean area), Level B (complex or small-quantity hazardous with local exhaust/containment), and Level C (hazardous compounding requiring negative pressure, dedicated C-PEC, and ISO standards).
- Master Formulation Records (the recipe detailing ingredients, instructions, and BUD justification) and Compounding Records (the individual batch log detailing lots, weights, and verifier initials) are legally mandatory quality assurance records.
- Default Beyond-Use Dates (BUDs) under NAPRA/USP <795> without specific stability data are: 14 days refrigerated (2-8°C) for water-containing oral liquids, 30 days room temperature for water-containing topicals/semi-solids, and 6 months (or earliest component expiry) for non-aqueous formulations.
- Crucial compounding techniques include geometric dilution for uniform blending of potent powders, levigation with an insoluble wetting agent to reduce particle size, and pulverization by intervention for crystalline materials using a volatile solvent.
- Equipment verification requires knowledge of balance sensitivity and the Minimum Weighable Quantity (MWQ) formula: $\text{MWQ} = \frac{\text{Sensitivity Requirement}}{\text{Maximum Allowable Error \%}}$, ensuring weighing errors never exceed 5%.
8.3 Non-Sterile Compounding and NAPRA Standards
Exam Focus: The National Association of Pharmacy Regulatory Authorities (NAPRA) non-sterile compounding standards mandate rigorous facility requirements, risk-level assessments, documentation systems, Beyond-Use Dating (BUD), and quality assurance procedures that candidates must master for the PEBC Evaluating Examination.
NAPRA Compounding Framework and Risk Categorization
In Canada, pharmacy compounding is governed by provincial adoption of the NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations and Health Canada Policy 0051 (distinguishing compounding from manufacturing). Compounding is defined as the preparation of a customized therapeutic product pursuant to a specific patient-prescriber relationship, whereas manufacturing involves industrial batch production with a Drug Identification Number (DIN).
+-------------------------------------------------------------------------+
| NAPRA NON-STERILE COMPOUNDING RISK LEVELS |
+-------------------------------------------------------------------------+
| |
| [LEVEL A: SIMPLE / BASELINE COMPOUNDING] |
| - Simple formulations, non-hazardous active ingredients |
| - Dedicated clean, uncluttered space; smooth non-porous surfaces |
| - Away from high-traffic workflows and air currents |
| |
| [LEVEL B: COMPLEX / INTERMEDIATE COMPOUNDING] |
| - Specialized equipment (e.g., capsule machines, homogenizers) |
| - Small quantities of hazardous powders generating airborne dust |
| - Dedicated enclosed room; local exhaust / Containment Enclosure (CVE) |
| |
| [LEVEL C: HAZARDOUS NON-STERILE COMPOUNDING] |
| - High-risk NIOSH hazardous drugs (e.g., antineoplastics, hormones) |
| - Negative pressure room (-0.01 to -0.03 inches of water column) |
| - Externally vented C-PEC (Class I BSC or CVE with HEPA filtration) |
| - Minimum 12 Air Changes Per Hour (ACPH) |
| |
+-------------------------------------------------------------------------+
| Level | Facility & Environmental Requirements | Equipment & Ventilation | Representative Preparations |
|---|---|---|---|
| Level A | Dedicated compounding zone within dispensary; smooth, impermeable, cleanable surfaces. | Standard calibrated balances, mortars/pestles, hot plates. No specialized exhaust required. | Simple topical creams/ointments (e.g., hydrocortisone in Glaxal base), non-hazardous oral suspensions (e.g., omeprazole in sodium bicarbonate). |
| Level B | Enclosed separate room separated from dispensary; dedicated wash station and surfaces. | Containment Ventilated Enclosure (CVE) or powder hood if handling irritating/dusty powders. | Multi-ingredient complex troches, bulk capsule formulations, compounding with minor volatile irritants. |
| Level C | Negative pressure room ($-0.01\text{ to }-0.03\text{ inches w.g.}$), minimum $12\text{ ACPH}$, sealed doors. | Externally vented Containment Primary Engineering Control (C-PEC; Class I BSC or CVE with HEPA). | Hazardous hormone powders (e.g., testosterone, progesterone, estradiol), hazardous cytotoxic powders (e.g., methotrexate, hydroxyurea suspensions). |
Mandatory Documentation: MFR versus Compounding Record
NAPRA standards mandate two distinct, interdependent levels of documentation for every compounded preparation:
1. Master Formulation Record (MFR) - "The Recipe"
The MFR is the approved, immutable master blueprint designed before compounding. It details:
- Official or assigned name, strength, and dosage form of the preparation.
- Complete list of active and inactive ingredients with exact quantities and chemical grades (e.g., USP, NF, BP grade; Certificate of Analysis [CoA] required for bulk powders).
- Step-by-step compounding instructions, mixing speeds, temperatures, and equipment required.
- Stability literature citations justifying the assigned Beyond-Use Date (BUD) and storage conditions.
- Container-closure system specifications (e.g., light-resistant amber glass, airtight pump).
- Quality control parameters (e.g., physical appearance, pH range, weight variation tolerance, color, odor).
- Patient counseling requirements and auxiliary warnings.
2. Compounding Record (Log) - "The Batch History"
The Compounding Record is the individualized, legal execution log completed for each specific batch. It records:
- Reference to the underlying Master Formulation Record (MFR).
- Exact manufacturer, lot numbers, and expiration dates of all raw ingredients used.
- Actual measured weights and volumes (including signed balance verification tapes).
- Internal lot number and assigned BUD specific to that batch.
- Initials/signatures of the compounding personnel (technician/student) and the verifying pharmacist.
- Total quantity compounded and percentage yield.
- Documented quality control check results (e.g., physical appearance, measured pH).
Beyond-Use Dating (BUD) for Non-Sterile Preparations
In the absence of specific, validated stability-indicating studies in peer-reviewed literature, pharmacists must strictly apply conservative default BUD limits established under NAPRA and USP <795>.
+-------------------------------------------------------------------------+
| DEFAULT NON-STERILE BUD MATRIX |
+-------------------------------------------------------------------------+
| |
| [NON-AQUEOUS FORMULATIONS] |
| - Ointments, non-aqueous gels, powders, capsules, suppositories |
| - BUD: Earliest API expiration date OR 6 MONTHS (Whichever is shorter) |
| - Storage: Controlled Room Temperature (20°C - 25°C) |
| |
| [WATER-CONTAINING ORAL FORMULATIONS] |
| - Aqueous oral suspensions, oral solutions, syrups |
| - BUD: Maximum 14 DAYS |
| - Storage: Controlled Refrigeration (2°C - 8°C) |
| |
| [WATER-CONTAINING TOPICAL / DERMAL / MUCOSAL SEMI-SOLIDS] |
| - Aqueous creams, lotions, topical gels |
| - BUD: Maximum 30 DAYS |
| - Storage: Controlled Room Temperature (20°C - 25°C) |
| |
+-------------------------------------------------------------------------+
Rule of Precedence: If any raw chemical component has an expiration date shorter than the default BUD period, the preparation's BUD must never exceed that component's expiration date.
Pharmaceutical Compounding Techniques and Excipients
Powder Blending and Particle Size Reduction
- Trituration: Continuous rubbing or grinding of a solid substance in a mortar with a pestle to reduce particle size to a fine powder (comminution) or to blend powders.
- Porcelain Mortar: Rough interior surface, ideal for comminution of hard crystalline materials.
- Glass Mortar: Non-porous, smooth surface, ideal for blending liquids, staining chemicals (e.g., iodine), or suspensions.
- Wedgewood Mortar: Porous, durable ceramic, preferred for grinding powders.
- Levigation ("Wet Grinding"): Reducing the particle size of a solid by grinding it in a mortar or spatulating it on an ointment slab with a small amount of a viscous liquid (levigating agent) in which the solid is insoluble.
- Mineral Oil: Preferred levigating agent for oleaginous/hydrophobic bases (e.g., white petrolatum, Aquaphor).
- Glycerin / Propylene Glycol: Preferred levigating agents for aqueous/water-washable bases (e.g., Glaxal base, Cetaphil, PEG ointment).
- Geometric Dilution: A critical blending technique used when mixing a potent active drug powder of small quantity with a large volume of inert diluent. The potent drug is combined with an equal volume of diluent, thoroughly triturated, and the process is repeated exponentially (doubling volume each step) to ensure homogeneous distribution.
- Pulverization by Intervention: Used for gummy or crystalline substances that resist mechanical grinding (e.g., camphor, iodine). A volatile solvent (such as ethanol) is added to dissolve the substance, triturated on an ointment tile, and as the solvent evaporates, the drug recrystallizes as an ultra-fine powder.
Physicochemical Stability and Degradation Pathways
- Hydrolysis: Cleavage of chemical bonds by water, common in esters (e.g., aspirin), amides (e.g., lidocaine), and lactams (e.g., penicillins). Prevented by lyophilization, non-aqueous solvents, and buffering.
- Oxidation: Electron loss catalyzed by light, oxygen, or trace heavy metals, causing color change (e.g., epinephrine turns pink/brown). Prevented by adding antioxidants (e.g., ascorbic acid, sodium metabisulfite, BHT) and chelating agents (e.g., EDTA).
Balance Sensitivity and Minimum Weighable Quantity (MWQ)
When using a Class A prescription torsion balance or electronic balance, the Minimum Weighable Quantity (MWQ) ensures that the relative weighing error does not exceed the accepted professional tolerance of $5%$ ($0.05$):
Example: For a Class A torsion balance with a Sensitivity Requirement (SR) of $6\text{ mg}$, the $\text{MWQ} = \frac{6\text{ mg}}{0.05} = 120\text{ mg}$. Weighing any quantity below $120\text{ mg}$ directly on this balance creates an unacceptable error exceeding $5%$, requiring an aliquot dilution.
A compounding pharmacist prepares a 100 mL oral aqueous suspension of spironolactone using spironolactone bulk powder USP, Ora-Plus suspending vehicle, and Ora-Sweet flavoring syrup. No published stability-indicating studies exist for this specific formulation, and all commercial ingredients have manufacturer expiration dates exceeding one year. Under NAPRA/USP <795> standards, what is the maximum Beyond-Use Date (BUD) and storage condition that may be assigned?
A community pharmacy plans to compound customized topical creams containing micronized progesterone powder and estradiol powder on a routine basis. According to NAPRA non-sterile compounding standards, which facility design and engineering controls are mandatory for handling these hazardous active pharmaceutical ingredients?
A pharmacist is using a Class A prescription torsion balance that possesses a certified Sensitivity Requirement (SR) of 6 mg. To ensure that the maximum allowable weighing error does not exceed 5%, what is the Minimum Weighable Quantity (MWQ) that can be measured directly on this balance?
A pharmacist is compounding an ointment containing insoluble salicylic acid powder incorporated into white petrolatum base. To prevent a gritty texture and ensure uniform particle reduction, the pharmacist rubs the powder with a small volume of mineral oil on an ointment tile prior to incorporating the petrolatum. Which compounding technique does this step describe?